ArticleEye (London, England)2026
Prevalence of intraretinal and subretinal fluid in acute non-arteritic anterior ischemic optic neuropathy.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis cross-sectional study aimed to characterise the prevalence and severity of intraretinal (IRF) and subretinal fluid (SRF) in in non-arteritic ischemic optic neuropathy (NAION).
methodsTwo neuro-ophthalmologists assessed optical coherence tomography scans of patients diagnosed with acute NAION at a tertiary neuro-ophthalmology centre between July 2022 and July 2024 for peripapillary SRF, peripapillary IRF, and foveal SRF.
resultsSixty-eight eyes (median age 65.0 years, 32.4% female) were seen across a median follow-up of 10.6 weeks (interquartile range 5.8-28.5 weeks). Peripapillary SRF was present in five (7.4%) cases (height range 57.0-216.0 μm), peripapillary IRF in 32 (47.1%, height range 103.0-364.0 μm), and foveal SRF in six (8.8%, height range 51.0-288.0 μm). Peripapillary SRF did not extend beyond a quarter of the distance from the disc margin to the fovea, but peripapillary IRF extended more than halfway in 9 (28.1%) cases. Compared to patients without peripapillary IRF, patients with peripapillary IRF had a greater baseline pRNFL thickness (P = 0.02) and smaller CDRs in the unaffected eye (average CDR, P = 0.002). The presence of foveal SRF was associated with the presence of peripapillary IRF (P = 0.008), greater peripapillary IRF height (P = 0.003), and foveal peripapillary IRF extension (P = 0.003). The presence and severity of peripapillary SRF, peripapillary IRF, and foveal SRF were not associated with initial nor final visual function.
conclusionsPeripapillary IRF restricted to the peripapillary region occurs in one-third of acute NAION cases but peripapillary IRF extending more than 50% to the fovea, peripapillary SRF, and foveal SRF are uncommon. Patients with smaller optic discs and more severe disc oedema may be more likely to develop peripapillary IRF and foveal SRF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.